RPRX Strangle Strategy
RPRX (Royalty Pharma plc), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
RPRX (Royalty Pharma plc) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $22.90B, a trailing P/E of 27.79, a beta of 0.40 versus the broader market, a 52-week range of 32.15-53.29, average daily share volume of 3.3M, a public-listing history dating back to 2020, approximately 75 full-time employees. These structural characteristics shape how RPRX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.40 indicates RPRX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. RPRX pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a strangle on RPRX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current RPRX snapshot
As of May 15, 2026, spot at $52.75, ATM IV 30.50%, IV rank 16.35%, expected move 8.74%. The strangle on RPRX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on RPRX specifically: RPRX IV at 30.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a RPRX strangle, with a market-implied 1-standard-deviation move of approximately 8.74% (roughly $4.61 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RPRX expiries trade a higher absolute premium for lower per-day decay. Position sizing on RPRX should anchor to the underlying notional of $52.75 per share and to the trader's directional view on RPRX stock.
RPRX strangle setup
The RPRX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RPRX near $52.75, the first option leg uses a $55.39 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RPRX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RPRX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $55.39 | N/A |
| Buy 1 | Put | $50.11 | N/A |
RPRX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
RPRX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on RPRX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on RPRX
Strangles on RPRX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the RPRX chain.
RPRX thesis for this strangle
The market-implied 1-standard-deviation range for RPRX extends from approximately $48.14 on the downside to $57.36 on the upside. A RPRX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current RPRX IV rank near 16.35% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on RPRX at 30.50%. As a Healthcare name, RPRX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RPRX-specific events.
RPRX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RPRX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RPRX alongside the broader basket even when RPRX-specific fundamentals are unchanged. Always rebuild the position from current RPRX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on RPRX?
- A strangle on RPRX is the strangle strategy applied to RPRX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With RPRX stock trading near $52.75, the strikes shown on this page are snapped to the nearest listed RPRX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are RPRX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the RPRX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 30.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a RPRX strangle?
- The breakeven for the RPRX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RPRX market-implied 1-standard-deviation expected move is approximately 8.74%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on RPRX?
- Strangles on RPRX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the RPRX chain.
- How does current RPRX implied volatility affect this strangle?
- RPRX ATM IV is at 30.50% with IV rank near 16.35%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.